Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Naveen, Deenadayalu"'
Autor:
Karen Brown, Sabina A. Murphy, Petr Jarolim, David A. Morrow, Julia F Kuder, Naveen Deenadayalu, Joshua Betcher, Elliott M. Antman, Christian T. Ruff, Robert P. Giugliano, Minggao Shi, Michele Mercuri, Eugene Braunwald, Indravadan Patel
Publikováno v:
The Lancet. 385:2288-2295
Summary Background New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vitamin K antagonists. A concern h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f36614ba2a57f35d1a5cd665c38b03b3
https://doi.org/10.1016/s0140-6736(14)61943-7
https://doi.org/10.1016/s0140-6736(14)61943-7
Autor:
Naveen Deenadayalu, Marc P. Bonaca, Marc S. Sabatine, David A. Morrow, Eugene Braunwald, Erin Bohula-May, L. Kristin Newby, Petr Jarolim, Jonathan Grinstein, Robert P. Giugliano, Michael J. Conrad
Publikováno v:
Clinical Cardiology. 38:230-235
Background High-sensitivity cardiac troponin T (hsTnT) is used in many countries, but is not available in the United States. Prior evidence has been viewed as inconclusive as to whether low cardiac troponin T (cTnT) concentrations detected with hsTnT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6458344c383e267f4da8cc9cc30dfe70
https://doi.org/10.1002/clc.22379
https://doi.org/10.1002/clc.22379
Autor:
Ilaria Cavallari, Naveen Deenadayalu, Minggao Shi, Christian T. Ruff, Robert P. Giugliano, Howard Rutman, Elliott M. Antman, Francesco Nordio, Hans Lanz, Michele Mercuri, Eugene Braunwald
Publikováno v:
International journal of cardiology. 257
Background Patients with atrial fibrillation (AF) who interrupt anticoagulation are at high risk of thromboembolism and death. Methods and results Patients enrolled in the ENGAGE AF-TIMI 48 trial (randomized comparison of edoxaban vs. warfarin) who i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cba63e62b4c58694c9854ee708889d1c
https://pubmed.ncbi.nlm.nih.gov/30223341
https://pubmed.ncbi.nlm.nih.gov/30223341
Autor:
Naveen Deenadayalu, Elliott M. Antman, Michele Mercuri, Eugene Braunwald, Abby Cange, Laura T. Grip, Valentin Curt, Sabina A. Murphy, Andrea E. Crompton, Joshua Betcher, Christian T. Ruff, Robert P. Giugliano
Publikováno v:
Journal of the American College of Cardiology. 64:576-584
Background At the end of 2 previous trials, an excess of stroke and bleeding was observed in patients with AF randomized to a new oral anticoagulant (NOAC) who transitioned to a vitamin K antagonist (VKA). Objectives The ENGAGE AF–TIMI 48 (Effectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55cc338367e7dc85ffad66e7d845a6f1
https://doi.org/10.1016/j.jacc.2014.05.028
https://doi.org/10.1016/j.jacc.2014.05.028
Autor:
Sabina A. Murphy, Giulia Magnani, Naveen Deenadayalu, Julia F Kuder, Eugene Braunwald, Marc P. Bonaca, Philippe Gabriel Steg, Pierre Théroux, Robert F. Storey, Anthony J. Dalby, Shinya Goto, Ramón Corbalán, Diego Ardissino, Marc S. Sabatine, Assen Goudev, Peter Held, Jose Lopez-Sendon, Eva C. Jensen, Jose C. Nicolau, Deepak L. Bhatt
Publikováno v:
Circulation. 132
Background: Long-term dual antiplatelet therapy with aspirin plus ticagrelor, a direct-acting reversibly-binding P2Y12 receptor antagonist, was recently shown in the PEGASUS-TIMI 54 trial (NCT01225562) to be superior to aspirin alone in preventing ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27bba035800abdb3a3dff203720a225c
https://doi.org/10.1161/circ.132.suppl_3.17121
https://doi.org/10.1161/circ.132.suppl_3.17121
Autor:
Marc S. Sabatine, Alexander G. Vandell, Francesco Nordio, Naveen Deenadayalu, James Lee, Sabina A. Murphy, Jessica L. Mega, Elliott M. Antman, Joseph R. Walker, Michele Mercuri, Eugene Braunwald, Christian T. Ruff, Robert P. Giugliano
Publikováno v:
Lancet (London, England). 385(9984)
Warfarin is the most widely used oral anticoagulant worldwide, but serious bleeding complications are common. We tested whether genetic variants can identify patients who are at increased risk of bleeding with warfarin and, consequently, those who wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1513d398a9291426ca1a570c4a3f5f85
https://pubmed.ncbi.nlm.nih.gov/25970639
https://pubmed.ncbi.nlm.nih.gov/25970639
Autor:
Jonathan, Grinstein, Marc P, Bonaca, Petr, Jarolim, Michael J, Conrad, Erin, Bohula-May, Naveen, Deenadayalu, Eugene, Braunwald, Robert P, Giugliano, L Kristin, Newby, Marc S, Sabatine, David A, Morrow
Publikováno v:
Clinical cardiology. 38(4)
BACKGROUND: High‐sensitivity cardiac troponin T (hsTnT) is used in many countries, but is not available in the United States. Prior evidence has been viewed as inconclusive as to whether low cardiac troponin T (cTnT) concentrations detected with hs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4ebd7e18182e1af53a73fb6348d84fab
https://pubmed.ncbi.nlm.nih.gov/25737394
https://pubmed.ncbi.nlm.nih.gov/25737394
Autor:
Christian T, Ruff, Robert P, Giugliano, Eugene, Braunwald, Michele, Mercuri, Valentin, Curt, Joshua, Betcher, Laura, Grip, Abby L, Cange, Andrea E, Crompton, Sabina A, Murphy, Naveen, Deenadayalu, Elliott M, Antman
Publikováno v:
Journal of the American College of Cardiology. 64(6)
At the end of 2 previous trials, an excess of stroke and bleeding was observed in patients with AF randomized to a new oral anticoagulant (NOAC) who transitioned to a vitamin K antagonist (VKA).The ENGAGE AF-TIMI 48 (Effective Anticoagulation with Fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f6f9f9fd1e3886e513dab0644bafb64b
https://pubmed.ncbi.nlm.nih.gov/25104528
https://pubmed.ncbi.nlm.nih.gov/25104528
Autor:
Christian Ruff, Robert Giugliano, Michele Mercuri, Naveen Deenadayalu, Elliott M. Antman, Andrea Elizabeth Crompton, Sabina Murphy, Jeffrey I. Weitz, James D. Douketis
Publikováno v:
Journal of the American College of Cardiology. 65:A2092
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed74977296e0a4669e22c3813f62219
https://doi.org/10.1016/s0735-1097(15)62092-7
https://doi.org/10.1016/s0735-1097(15)62092-7
Autor:
Petr Jarolim, Michele Mercuri, Eugene Braunwald, Indravadan Patel, Karen Brown, Minggao Shi, Joshua Betcher, Christian T. Ruff, Naveen Deenadayalu, Robert P. Giugliano, Elliott M. Antman, David A. Morrow, Sabina A. Murphy
Publikováno v:
Journal of the American College of Cardiology. 63:A329
High (HD) and low doses (LD) of the FXa inhibitor edoxaban (edox) were noninferior to warfarin in preventing stroke/systemic embolism (stroke/SEE) with less bleeding in the ENGAGE-AF trial of 21,105 pts with AF. Dose was reduced 50% for impaired drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f222d86cb974aec370c49e6369aac405
https://doi.org/10.1016/s0735-1097(14)60329-6
https://doi.org/10.1016/s0735-1097(14)60329-6